Podcast: Play in new window | Download
Subscribe: RSS
David Traylor is Senior Managing Director at Golden Eagle Partners, and organizer of the CannMed 24 Capital Markets Workshop.
After advising on various transactions in the life science sector, David took an interest in the cannabis sector and started advising cannabis companies before eventually re-foundeding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value.
David and Golden Eagle Partners will host a Capital Markets Workshop at CannMed 24 which will explore a global perspective of the hurdles, issues, and concepts around funding cannabinoid and cannabis innovation.
During our conversation we discuss:
- What attendees can expect from the Capital Markets Workshop
- Redefining the cannabis nomenclature
- The likelihood the DEA will reschuelde cannabis this year
- Pharma’s growing interest in cannabis-derived compounds
- Challenges cannabis innovators face when raising capital
Thanks to This Episode’s Sponsor: Golden Eagle Partners
Golden Eagle Partners are transactional experts, specializing in mergers, acquisitions, reverse mergers, financings and incremental transactions such as licensing, joint ventures and co-development arrangements. Their combined experience in the early stages of the cannabis and life science sectors allows them to confidently close strategic and financing transactions that match the near- and long-term goals of their clients.
Learn more at goldeneaglepartners.com
Additional Resources